Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$50 Mln
P/E Ratio
--
P/B Ratio
7.08
Industry P/E
--
Debt to Equity
0.03
ROE
-2.05 %
ROCE
-192.93 %
Div. Yield
0 %
Book Value
0.32
EPS
-0.89
CFO
$-51.78 Mln
EBITDA
$-60.02 Mln
Net Profit
$-60.63 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Gain Therapeutics (GANX)
| -16.48 | -14.50 | -23.88 | -42.91 | -22.26 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Gain Therapeutics (GANX)
| -33.62 | 4.31 | -42.36 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.14 | 10,226.85 | 20.76 | 23.13 | |
| 296.71 | 9,219.66 | 24.15 | 58.42 | |
| 24.49 | 10,361.50 | -- | -28.77 | |
| 100.99 | 9,388.25 | 28.84 | 14.16 |
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies... proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland. Address: 4800 Montgomery Lane, Bethesda, MD, United States, 20814 Read more
Founder & Chairman
Dr. Khalid Islam Ph.D.
Founder & Chairman
Dr. Khalid Islam Ph.D.
Headquarters
Bethesda, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Gain Therapeutics Inc (GANX) stood at $ 12 Mln as on 31-Dec-24
The share price of Gain Therapeutics Inc (GANX) is $1.80 (NASDAQ) as of 17-Apr-2025 13:44 EDT. Gain Therapeutics Inc (GANX) has given a return of -22.26% in the last 3 years.
Gain Therapeutics Inc (GANX) has a market capitalisation of $ 50 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Gain Therapeutics Inc (GANX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Gain Therapeutics Inc (GANX) and enter the required number of quantities and click on buy to purchase the shares of Gain Therapeutics Inc (GANX).
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland. Address: 4800 Montgomery Lane, Bethesda, MD, United States, 20814
The CEO & director of Dr. Khalid Islam Ph.D.. is Gain Therapeutics Inc (GANX), and CFO & Sr. VP is Dr. Khalid Islam Ph.D..
There is no promoter pledging in Gain Therapeutics Inc (GANX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Gain Therapeutics Inc. (GANX) | Ratios |
|---|---|
|
Return on equity(%)
|
-204.95
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Gain Therapeutics Inc (GANX) was $0 Mln.
$0.06
(
